Arteris (AIP) director Janac records 40,000-share 10b5-1 stock sale
Rhea-AI Filing Summary
Arteris, Inc. director K. Charles Janac reported an indirect sale of company stock executed under a pre-arranged trading plan. On December 4, 2025, an entity he manages, Bayview Legacy, LLC, sold 40,000 shares of Arteris common stock at a weighted average price of $16.4618 per share under a Rule 10b5-1 plan adopted on March 5, 2025. Following this transaction, Janac beneficially owned 9,599,071 shares of Arteris common stock indirectly through Bayview Legacy, LLC.
Positive
- None.
Negative
- None.
FAQ
What insider stock transaction did Arteris (AIP) disclose for K. Charles Janac?
Arteris disclosed that director K. Charles Janac, through Bayview Legacy, LLC, sold 40,000 shares of Arteris common stock in a reported transaction.
On what date and at what price were the Arteris (AIP) shares sold by K. Charles Janac?
The sale occurred on December 4, 2025 at a weighted average price of $16.4618 per share, with individual trades ranging from $16.25 to $16.65.
How many Arteris (AIP) shares does K. Charles Janac beneficially own after the reported sale?
After the reported sale, K. Charles Janac beneficially owned 9,599,071 shares of Arteris common stock indirectly through Bayview Legacy, LLC.
Was the Arteris (AIP) insider sale made under a Rule 10b5-1 trading plan?
Yes. The transaction was made pursuant to a Rule 10b5-1 trading plan that was adopted by K. Charles Janac on March 5, 2025.
What is Bayview Legacy, LLC’s role in K. Charles Janac’s Arteris (AIP) holdings?
Bayview Legacy, LLC holds the Arteris shares, and K. Charles Janac, as its manager, is deemed to have voting and dispositive power over those shares.
Does K. Charles Janac have another report related to this Arteris (AIP) transaction?
Yes. He has separately filed a report in his individual capacity for the same transaction due to his beneficial ownership of the shares through Bayview Legacy, LLC.